Takeda’s Oveporexton: A Promising Step

Takeda Pharmaceuticals has announced positive results from a pivotal Phase 3 trial of oveporexton, a novel therapy targeting orexin deficiency in patients with narcolepsy. According to BioPharmaDive.com, this development marks…

Continue Reading Takeda’s Oveporexton: A Promising Step
SLEEP 2024: Presented Data Highlighted Possible Benefits of ALKS 2680 for Narcolepsy Type 1
https://pixabay.com/en/bed-sleep-girl-white-tired-pillow-945881/

SLEEP 2024: Presented Data Highlighted Possible Benefits of ALKS 2680 for Narcolepsy Type 1

The American Academy of Sleep Medicine and the Sleep Research Society held the 38th annual SLEEP meeting in early June 2024. The meeting allows stakeholders across the sleep sphere to…

Continue Reading SLEEP 2024: Presented Data Highlighted Possible Benefits of ALKS 2680 for Narcolepsy Type 1